Item 8.01. Other Events.
On January 21, 2020, Innovate Biopharmaceuticals, Inc. (the "Company") entered
into a letter agreement (the "Letter Agreement") with RDD Pharma Ltd. ("RDD"),
INNT Merger Sub 1 Ltd. ("Merger Sub") and OrbiMed Israel Partners, Limited
Partnership (the "Shareholder Representative"). Pursuant to the Letter
Agreement, the Company, RDD, Merger Sub and the Shareholder Representative
agreed to waive certain terms of the Agreement and Plan of Merger and
Reorganization, as amended, (the "Merger Agreement") previously filed with the
Securities and Exchange Commission on October 7, 2019 and December 17, 2019.
Except as waived in the Letter Agreement, all of the terms and conditions set
forth in the Merger Agreement remain in full force and effect.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibit No. Description
Exhibit 99.1 Letter Agreement, dated January 21, 2020
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses